Valuation: HYUNDAI BIOLAND Co.,Ltd.

Capitalization 152B 110M 96.23M 90.39M 82.2M 152M 9.58B 171M 1.07B 412M 4.37B 414M 405M 16.08B P/E ratio 2025 *
8.31x
P/E ratio 2026 * 7.24x
Enterprise value 151M 109K 95.21K 89.44K 81.34K 150K 9.48M 169K 1.06M 407K 4.32M 410K 401K 15.91M EV / Sales 2025 *
1.02x
EV / Sales 2026 * 0.83x
Free-Float
65%
Yield 2025 *
1.28%
Yield 2026 * 1.36%
More valuation ratios * Estimated data
Dynamic Chart
HYUNDAI BIOLAND Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 May. 15 CI
HYUNDAI BIOLAND Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 Mar. 11 CI
HYUNDAI BIOLAND Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 14 CI
HYUNDAI BIOLAND Co.,Ltd.(KOSDAQ:A052260) dropped from S&P Global BMI Index 24-09-22 CI
HYUNDAI BIOLAND Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 24-08-14 CI
HYUNDAI BIOLAND Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 24-05-16 CI
HYUNDAI BIOLAND Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 24-03-12 CI
HYUNDAI BIOLAND Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 23-03-10 CI
Hyundai HCN Co.,Ltd. completed the acquisition of 27.94% stake in SKbioland Co., Ltd. from SKC Co., Ltd.. 20-10-05 CI
Hyundai HCN Co.,Ltd. agreed to acquire 27.94% stake in SKbioland Co., Ltd. from SKC Co., Ltd. for approximately KRW 120 billion. 20-08-17 CI
UCI Co.,Ltd. acquired 30.9% stake in Bio X Co., Ltd. from group of sellers for KRW 20 billion. 20-03-02 CI
UCI Co.,Ltd. announced that it has received KRW 20 billion in funding from Pacific Invest Fund, SKbioland Co., Ltd., L&K Investment Co., Ltd. and other investors 20-03-02 CI
SKC Co. Ltd. completed the acquisition of an additional 4.39% stake in Bioland Co., Ltd. from Chan Bok Jeong. 15-07-13 CI
More news
1 day+0.40%
1 week-1.36%
Current month+7.51%
1 month+16.78%
3 months+13.01%
6 months+20.24%
Current year+12.51%
More quotes
1 week 4,950
Extreme 4950
5,220
1 month 4,275
Extreme 4275
5,240
Current year 3,825
Extreme 3825
5,240
1 year 3,825
Extreme 3825
6,520
3 years 3,825
Extreme 3825
9,225
5 years 3,825
Extreme 3825
19,475
10 years 3,825
Extreme 3825
24,425
More quotes
Manager TitleAgeSince
Chief Executive Officer 57 2020-10-05
Director TitleAgeSince
Director/Board Member 62 2020-03-24
Director/Board Member 51 2020-03-24
Director/Board Member 57 2020-08-27
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.40%-1.36%-1.93%-21.85% 110M
+0.85%-1.17%-17.16%+18.87% 223B
+0.98%+1.62%+49.15% - 32.49B
-0.52%-2.15%-2.12%+25.61% 20.98B
+0.53%+0.88%-47.11%-51.41% 6.69B
+1.14%-1.70%-25.28%-4.44% 5.97B
-1.46%-4.20%-25.71%-29.83% 4.44B
-1.89%-6.16%+19.37%+100.14% 4.27B
-3.04%-4.77%-50.97%-31.96% 4.18B
-1.68%-5.66%+79.16% - 3.89B
Average -0.46%-2.24%-2.26%+0.64% 30.58B
Weighted average by Cap. +0.62%-2.71%-8.74%+16.81%
See all sector performances

Financials

2025 *2026 *
Net sales 148B 107M 93.64M 87.96M 79.99M 148M 9.33B 166M 1.04B 401M 4.25B 403M 394M 15.65B 166B 120M 104M 98.16M 89.27M 165M 10.41B 186M 1.16B 447M 4.74B 450M 440M 17.47B
Net income 18.3B 13.25M 11.55M 10.85M 9.87M 18.2M 1.15B 20.53M 128M 49.44M 524M 49.73M 48.66M 1.93B 21.1B 15.28M 13.32M 12.51M 11.38M 20.99M 1.33B 23.67M 148M 57.01M 605M 57.33M 56.11M 2.23B
Net Debt -1.6B -1.16M -1.01M -949K -863K -1.59M -101M -1.8M -11.2M -4.32M -45.84M -4.35M -4.25M -169M -14.5B -10.5M -9.16M -8.6M -7.82M -14.42M -912M -16.27M -101M -39.18M -415M -39.4M -38.56M -1.53B
More financial data * Estimated data
Logo HYUNDAI BIOLAND Co.,Ltd.
Hyundai Bioland Co Ltd, formerly SK Bio Land Co Ltd, is a Korea-based company mainly engaged in the development and manufacture of raw materials for cosmetics. The Company operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
Employees
320
More about the company
Date Price Change Volume
25-06-19 5,080.00 +0.40% 46,509
25-06-18 5,060.00 +0.20% 43,146
25-06-17 5,050.00 -0.98% 114,256
25-06-16 5,100.00 +0.20% 54,521
25-06-13 5,090.00 -1.17% 154,284

End-of-day quote Korea S.E., June 18, 2025

More quotes
Trading Rating
Investor Rating
ESG MSCI
More Ratings

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A052260 Stock